Samalin Investment Counsel, LLC Halozyme Therapeutics, Inc. Transaction History
Samalin Investment Counsel, LLC
- $207 Million
- Q2 2024
A detailed history of Samalin Investment Counsel, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Samalin Investment Counsel, LLC holds 11,952 shares of HALO stock, worth $676,961. This represents 0.3% of its overall portfolio holdings.
Number of Shares
11,952
Previous 12,492
4.32%
Holding current value
$676,961
Previous $508,000
23.03%
% of portfolio
0.3%
Previous 0.25%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
487Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$998 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$730 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$329 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$229 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$211 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.89B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...